+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07855133

Evaluating Tolerability When Switching From Semaglutide to Zenagamtide in Adults With Overweight or Obesity, With or Without Type 2 Diabetes

Led by Novo Nordisk A/S · Updated on 2026-10-16

60

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how adults with overweight or obesity, with or without type 2 diabetes, tolerate switching from their current semaglutide treatment to a new drug called zenagamtide. The study aims to find the best dose of zenagamtide that participants can switch to from a maintenance dose of semaglutide. This phase 1 study is sponsored by Novo Nordisk AS and focuses on treatment safety and tolerability. Participants will initially receive weekly subcutaneous injections of semaglutide using pre-filled pen-injectors applied to the thigh, abdomen, or upper arm. After completing their last maintenance dose of semaglutide, they will switch to weekly subcutaneous injections of zenagamtide at different dose levels, also administered via pre-filled pen-injectors. The study uses a sequential design to assess different zenagamtide dose levels. During the study, participants will be monitored for treatment-emergent adverse events from the first dose of zenagamtide through day 57. Researchers will also measure zenagamtide blood levels, including the area under the plasma concentration-time curve, maximum concentration, and time to maximum concentration during the first week after dosing. Screening involves medical history, physical exam, vital signs, ECG, and lab tests to confirm eligibility. The study will continue until September 2028, and all participants will receive both semaglutide and zenagamtide treatments under close observation.

CONDITIONS

Brief Title

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication

Research Team

N

Novo Nordisk

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here